Market Closed -
Nasdaq
02:00:01 07/05/2024 am IST
|
5-day change
|
1st Jan Change
|
62.19
USD
|
-4.00%
|
|
+10.90%
|
+479.59%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
821
|
547.2
|
495.2
|
3,358
|
-
|
-
|
Enterprise Value (EV)
1 |
821
|
547.2
|
495.2
|
3,358
|
3,358
|
3,358
|
P/E ratio
|
-14.2
x
|
-8.66
x
|
-8.13
x
|
-48
x
|
-39.5
x
|
-32.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
226
x
|
63.5
x
|
61.3
x
|
1,065
x
|
1,359
x
|
318
x
|
EV / Revenue
|
226
x
|
63.5
x
|
61.3
x
|
1,065
x
|
1,359
x
|
318
x
|
EV / EBITDA
|
-25
x
|
-8.26
x
|
-6.97
x
|
-33.4
x
|
-28.6
x
|
-
|
EV / FCF
|
-44.5
x
|
-8.16
x
|
-
|
-159
x
|
-36.5
x
|
-31.8
x
|
FCF Yield
|
-2.25%
|
-12.3%
|
-
|
-0.63%
|
-2.74%
|
-3.14%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,612
|
41,551
|
46,151
|
51,840
|
-
|
-
|
Reference price
2 |
19.73
|
13.17
|
10.73
|
64.78
|
64.78
|
64.78
|
Announcement Date
|
18/03/22
|
10/03/23
|
08/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3.637
|
8.612
|
8.083
|
3.153
|
2.471
|
10.55
|
EBITDA
1 |
-
|
-32.82
|
-66.25
|
-71.02
|
-100.5
|
-117.3
|
-
|
EBIT
1 |
-
|
-32.93
|
-67.09
|
-72.98
|
-87.16
|
-110.4
|
-132.7
|
Operating Margin
|
-
|
-905.39%
|
-779.04%
|
-902.87%
|
-2,764.37%
|
-4,468.9%
|
-1,257.83%
|
Earnings before Tax (EBT)
1 |
-
|
-32.67
|
-63.06
|
-59.29
|
-71.17
|
-94.65
|
-120.8
|
Net income
1 |
-6.784
|
-32.67
|
-63.06
|
-59.29
|
-72.9
|
-95.37
|
-120.8
|
Net margin
|
-
|
-898.32%
|
-732.22%
|
-733.55%
|
-2,312.14%
|
-3,858.78%
|
-1,144.68%
|
EPS
2 |
-7.416
|
-1.390
|
-1.520
|
-1.320
|
-1.350
|
-1.639
|
-1.993
|
Free Cash Flow
1 |
-
|
-18.46
|
-67.09
|
-
|
-21.1
|
-92.07
|
-105.5
|
FCF margin
|
-
|
-507.51%
|
-779.04%
|
-
|
-669.2%
|
-3,725.24%
|
-999.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/04/21
|
18/03/22
|
10/03/23
|
08/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.159
|
1.616
|
1.589
|
2.365
|
1.813
|
2.845
|
2.048
|
1.057
|
2.517
|
2.461
|
0.8724
|
0.8153
|
0.8224
|
0.6429
|
-
|
EBITDA
|
-10.88
|
-13.43
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-15.61
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.9
|
-13.49
|
-13.54
|
-17.26
|
-18.02
|
-18.27
|
-20.28
|
-20.75
|
-15.81
|
-16.14
|
-19.78
|
-20.91
|
-21.98
|
-22.68
|
-
|
Operating Margin
|
-940.72%
|
-834.78%
|
-852.23%
|
-729.85%
|
-994.04%
|
-642.04%
|
-990.28%
|
-1,962.91%
|
-628.25%
|
-655.71%
|
-2,267.15%
|
-2,564.24%
|
-2,672.09%
|
-3,527.9%
|
-
|
Earnings before Tax (EBT)
1 |
-10.77
|
-13.42
|
-13.41
|
-16.89
|
-16.7
|
-16.06
|
-17.46
|
-17.51
|
-11.57
|
-11.76
|
-16.98
|
-16.64
|
-17.72
|
-18.95
|
-
|
Net income
1 |
-10.77
|
-13.42
|
-13.41
|
-16.89
|
-16.7
|
-16.06
|
-17.46
|
-17.51
|
-11.57
|
-11.76
|
-17.6
|
-17.44
|
-18.39
|
-18.98
|
-
|
Net margin
|
-928.9%
|
-830.2%
|
-843.93%
|
-714.08%
|
-920.9%
|
-564.67%
|
-852.49%
|
-1,656.39%
|
-459.59%
|
-477.77%
|
-2,017.02%
|
-2,138.87%
|
-2,235.93%
|
-2,952.08%
|
-
|
EPS
2 |
-0.2600
|
-0.2900
|
-0.3200
|
-0.4100
|
-0.4000
|
-0.3900
|
-0.4200
|
-0.4200
|
-0.2500
|
-0.2500
|
-0.3312
|
-0.3225
|
-0.3450
|
-0.3575
|
-0.3067
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
18/03/22
|
10/05/22
|
09/08/22
|
10/11/22
|
10/03/23
|
09/05/23
|
08/08/23
|
07/11/23
|
08/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-18.5
|
-67.1
|
-
|
-21.1
|
-92.1
|
-105
|
ROE (net income / shareholders' equity)
|
-
|
-18.6%
|
-18.4%
|
-
|
-18.3%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-0.7200
|
-1.040
|
-
|
-0.4200
|
-0.7000
|
-1.170
|
Capex
1 |
-
|
-
|
-
|
-
|
1.7
|
1.83
|
1.9
|
Capex / Sales
|
-
|
-
|
-
|
-
|
53.92%
|
73.84%
|
18.01%
|
Announcement Date
|
16/04/21
|
18/03/22
|
10/03/23
|
08/03/24
|
-
|
-
|
-
|
Last Close Price
62.19
USD Average target price
58.29
USD Spread / Average Target -6.28% Consensus |
1st Jan change
|
Capi.
|
---|
| +479.59% | 3.36B | | +22.81% | 47.9B | | +46.56% | 41.42B | | -1.88% | 40.7B | | -6.20% | 28.92B | | +11.33% | 25.55B | | -21.00% | 19.27B | | -1.43% | 12.15B | | +30.73% | 12.14B | | -0.48% | 11.99B |
Other Biotechnology & Medical Research
|